Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...
Hosted on MSN11mon
Valneva GAAP EPS of -€0.73, revenue of €153.71M; updates FY24 guidance
Valneva press release (NASDAQ ... product tech transfers to Valneva’s brand-new state-of the art facility in Scotland. Other income is now expected between €100 million and €110 million ...
Pharmabiz8d
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...
Yahoo Finance8d
Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults ...
pharmaphorum2y
Readout sets up phase 3 for Valneva/Pfizer's Lyme disease jab
The news is a timely boost for Paris, France-based Valneva, which is facing uncertain ... are ongoing to supply 25,000 doses to the NHS in Scotland. Starting phase 3 testing of VLA15 will trigger ...
Business Insider12d
Valneva (0OB3) Gets a Buy from Kepler Capital
In a report released on January 31, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a price target of €8.10. The company’s shares closed ...
Yahoo Finance9d
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data, published in The Lancet ...